| Bioactivity | Inbakicept (ALT-803) is an IL-15 superagonist complex, consisting of IL-15 mutant and IL-15Rα-Fc fusion. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation, IFNγ production in cells[1]. |
| Invitro | Inbakicept (0.01-1 nM；20 小时) 增强人 NK 细胞的细胞毒性并增加细胞毒性效应分子的表达[1]。 Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | Inbakicept (0.2 mg/kg；静脉注射；每周两次，持续 2 周) 在小鼠模型中增强利妥昔单抗对致死性 Daudi 淋巴瘤攻击的保护作用[1]。 Animal Model: |
| Name | Inbakicept |
| CAS | 2135939-52-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rosario M, et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016 Feb 1;22(3):596-608. |